Phaseline

Companies › BioNTech SE

BioNTech SE: clinical trials, targets and expected readouts

23 active drug programs in 49 registered trials: 27 Phase 1, 11 Phase 2, 9 Phase 3, 2 Phase 4; Oncology, Infectious disease; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Tozinameran
Spike glycoprotein vaccine antigen
SARS-COV-2Phase 4COVID-19 Vaccines; COVID-19; Diabetes Mellitus, Type 1Apr 2027
Pumitamig (BNT327, BMS-986545, PM8002)–Phase 3Extensive-stage Small-cell Lung Cancer; Breast Neoplasms; Pancreatic Ductal Adenocarcinoma (PDAC); Recurrent Glioblastoma …Jun 2027
BNT323/DB-1303
anti-HER2 antibody-drug conjugate with topoisomerase I inhibitor payload
ERBB2Phase 3Endometrial CancerMar 2028
BNT324
B7-H3 antibody-drug conjugate
B7H3Phase 3Metastatic Castration-resistant Prostate Cancer; Advanced Lung CancerSep 2028
RO7198457–Phase 2Colorectal Cancer Stage II; Pancreatic CancerNov 2026
BNT166a
mRNA-based Mpox vaccine
–Phase 2Mpox (Monkeypox)Jun 2027
BNT113
HPV16-targeting immunotherapy
–Phase 2Unresectable Head and Neck Squamous Cell CarcinomaApr 2029
BNT314–Phase 1Advanced Malignant Solid Tumor; Metastatic Colorectal CancerNov 2026
BNT351
HIV-neutralizing antibody
–Phase 1HIV -1 InfectionNov 2026
BNT164a1
Multi-antigen RNA vaccine for active immunization against tuberculosis
–Phase 1TuberculosisJan 2027
BNT164b1
Multi-antigen RNA vaccine for active immunization against tuberculosis
–Phase 1TuberculosisJan 2027
BNT3212
Unclear - not specified in registry text
–Phase 1Advanced Solid TumorNov 2027
BNT168
RNA-based vaccine
–Phase 1HIV -1 InfectionFeb 2028
BNT326–Phase 1Advanced Solid Tumor; Non-small Cell Lung CancerMar 2028
BNT323
HER2-targeted antibody-drug conjugate (trastuzumab conjugated with panmitrimer)
ERBB2Phase 1Locally Advanced Breast CancerAug 2029
BNT116
mRNA vaccine encoding tumor-associated antigens
–Phase 1Non-Small Cell Lung CancerFeb 2030
BNT316
anti-CTLA-4 antibody
CTLA4Phase 1Non-Small Cell Lung CancerFeb 2030
anti-B7-H3 antibody conjugated to topoisomerase I inhibitor
anti-B7-H3 antibody-drug conjugate with topoisomerase I inhibitor
B7H3Phase 1Non-Small Cell Lung CancerFeb 2030
anti-HER3 antibody conjugated to topoisomerase I inhibitor
anti-HER3 antibody-drug conjugate with topoisomerase I inhibitor
HER3Phase 1Non-Small Cell Lung CancerFeb 2030
BNT329
CA19-9-targeting monoclonal antibody
–Phase 1Advanced Solid CancersMay 2030
BNT3214
Unclear - early phase exploratory drug
–Phase 1Advanced Solid Tumor CancerOct 2030
BNT317
Unclear - code-named investigational therapy
–Phase 1Advanced Solid TumorApr 2031
BNT163
Anti-viral RNA vaccine for active immunization against HSV-2
HSV2Phase 1Genital Herpes Simplex Type 2–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04894435TozinameranPhase 2COVID-19Infectious diseaseNov 2024
NCT04894435TozinameranPhase 2COVID-19Infectious diseaseNov 2024
NCT07300839TozinameranPhase 3COVID-19Infectious diseaseSep 2026
NCT05432583BNT163Phase 1Genital Herpes Simplex Type 2Infectious diseaseOct 2026
NCT04161755RO7198457Phase 1Pancreatic CancerOncologyNov 2026
NCT04486378RO7198457Phase 2Colorectal Cancer Stage IIOncologyNov 2026
NCT06150183BNT314Phase 1Advanced Malignant Solid TumorOncologyNov 2026
NCT07392372BNT351Phase 1HIV -1 InfectionInfectious diseaseNov 2026
NCT05415267TozinameranPhase 3COVID-19Infectious diseaseDec 2026
NCT05547464BNT164a1Phase 1TuberculosisInfectious diseaseJan 2027
NCT05547464BNT164b1Phase 1TuberculosisInfectious diseaseJan 2027
NCT07798648TozinameranPhase 3COVID-19 VaccinesInfectious diseaseApr 2027
NCT07798648TozinameranPhase 3COVID-19 VaccinesInfectious diseaseApr 2027
NCT07798648TozinameranPhase 3COVID-19 VaccinesInfectious diseaseApr 2027
NCT06449209Pumitamig (BNT327, BMS-986545, PM8002)Phase 2Extensive-stage Small-cell Lung CancerOncologyJun 2027
NCT07379580BNT166aPhase 2Mpox (Monkeypox)Infectious diseaseJun 2027
NCT07730450TozinameranPhase 4COVID-19 VaccinesInfectious diseaseAug 2027
NCT06452654TozinameranPhase 4Diabetes Mellitus, Type 1Infectious diseaseOct 2027
NCT07147348Pumitamig (BNT327, BMS-986545, PM8002)Phase 1Advanced Solid TumorOncologyNov 2027
NCT07147348BNT3212Phase 1Advanced Solid TumorOncologyNov 2027
NCT07255404Pumitamig (BNT327, BMS-986545, PM8002)Phase 2Pancreatic Ductal Adenocarcinoma (PDAC)OncologyDec 2027
NCT07297212Pumitamig (BNT327, BMS-986545, PM8002)Phase 2Recurrent GlioblastomaOncologyJan 2028
NCT07698600BNT168Phase 1HIV -1 InfectionInfectious diseaseFeb 2028
NCT07070232Pumitamig (BNT327, BMS-986545, PM8002)Phase 1Advanced Solid TumorOncologyMar 2028
NCT06340568BNT323/DB-1303Phase 3Endometrial CancerOncologyMar 2028
NCT07070232BNT326Phase 1Advanced Solid TumorOncologyMar 2028
NCT06449222Pumitamig (BNT327, BMS-986545, PM8002)Phase 2Locally Advanced Breast CancerOncologyAug 2028
NCT06892548Pumitamig (BNT327, BMS-986545, PM8002)Phase 1Advanced Lung CancerOncologySep 2028
NCT06892548BNT324Phase 1Advanced Lung CancerOncologySep 2028
NCT06841055Pumitamig (BNT327, BMS-986545, PM8002)Phase 2Non-small Cell Lung CancerOncologyOct 2028
NCT07111520Pumitamig (BNT327, BMS-986545, PM8002)Phase 1Non-small Cell Lung CancerOncologyNov 2028
NCT07111520BNT326Phase 1Non-small Cell Lung CancerOncologyNov 2028
NCT06712316Pumitamig (BNT327, BMS-986545, PM8002)Phase 2Non-small Cell Lung CancerOncologyJan 2029
NCT06712355Pumitamig (BNT327, BMS-986545, PM8002)Phase 3Extensive-stage Small-cell Lung CancerOncologyApr 2029
NCT04534205BNT113Phase 2Unresectable Head and Neck Squamous Cell CarcinomaOncologyApr 2029
NCT07579221Pumitamig (BNT327, BMS-986545, PM8002)Phase 1Non-Small Cell Lung CancerOncologyAug 2029
NCT06827236Pumitamig (BNT327, BMS-986545, PM8002)Phase 1Locally Advanced Breast CancerOncologyAug 2029
NCT06827236BNT323Phase 1Locally Advanced Breast CancerOncologyAug 2029
NCT07173751Pumitamig (BNT327, BMS-986545, PM8002)Phase 3Breast NeoplasmsOncologyDec 2029
NCT05142189BNT116Phase 1Non-Small Cell Lung CancerOncologyFeb 2030
NCT05142189BNT316Phase 1Non-Small Cell Lung CancerOncologyFeb 2030
NCT05142189anti-B7-H3 antibody conjugated to topoisomerase I inhibitorPhase 1Non-Small Cell Lung CancerOncologyFeb 2030
NCT05142189anti-HER3 antibody conjugated to topoisomerase I inhibitorPhase 1Non-Small Cell Lung CancerOncologyFeb 2030
NCT07186842BNT329Phase 1Advanced Solid CancersOncologyMay 2030
NCT07455734BNT3214Phase 1Advanced Solid Tumor CancerOncologyOct 2030
NCT07079631Pumitamig (BNT327, BMS-986545, PM8002)Phase 1Metastatic Colorectal CancerOncologyDec 2030
NCT07079631BNT314Phase 1Metastatic Colorectal CancerOncologyDec 2030
NCT07365995BNT324Phase 3Metastatic Castration-resistant Prostate CancerOncologyFeb 2031
NCT06750185BNT317Phase 1Advanced Solid TumorOncologyApr 2031

Specialist investors

Held by 5 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

ERBB2 (2) B7H3 (2) SARS-COV-2 (1) HSV2 (1) CTLA4 (1) HER3 (1)

Companies with the same targets

Beijing Biotech Roche Sichuan Baili Pharmaceutical AstraZeneca Shanghai Henlius Biotech Innovent Biopharmaceutical Technology (Hangzhou) Jiangsu HengRui Medicine Shenyang Sunshine Pharmaceutical CSPC Megalith Biopharmaceutical Suzhou Suncadia Biopharmaceuticals

Companies built like this

Sichuan Baili Pharmaceutical MediLink Therapeutics (Suzhou) Shanghai JMT-Bio ImmunityBio Shanghai Institute Of Biological Products

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.